N
Nkarta, Inc. (NKTX)
NMS – Real vaqt narxi. Valyuta: USD
3.28
+0.10 (3.14%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
3.28
+0.10 (3.14%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Nkarta, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saraton va otoimmün kasalliklarni davolash uchun tabiiy killer hujayralari terapiyasini ishlab chiqadi va tijoratlashtiradi. Uning asosiy mahsulot nomzodi NKX019, CD19 antigenini nishonga olgan ximerik antigen retseptorli tabiiy killer (CAR NK) bo'lib, u lupus nefriti; tizimli skleroz; idiopatik yallig'lanishli miyopatiya; va neytrofillarga qarshi sitoplazmatik antitelalar (ANCA) bilan bog'liq vaskulit, shuningdek, tizimli qizil yug'urish va miyasteniya gravisni davolash uchun 1-bosqich klinik sinovdan o'tmoqda. Kompaniya CRISPR Therapeutics AG bilan ilmiy-tadqiqot hamkorlik shartnomasiga ega. Nkarta, Inc. 2015-yilda tashkil etilgan va Janubiy San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Nadir Mahmood Ph.D. | President and Principal Accounting & Financial Officer |
| Dr. Shawn Rose M.D., Ph.D. | Chief Medical Officer and Head of Research & Development |
| Mr. Paul J. Hastings | CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-23 | DEF 14A | ny20064125x1_def14a.htm |
| 2026-04-01 | CORRESP | filename1.htm |
| 2026-03-26 | 8-K | nktx-20260325.htm |
| 2026-03-25 | S-3 | ny20068088x1_s3.htm |
| 2026-01-05 | S-8 | nktx-20260105.htm |
| 2025-11-10 | 10-Q | nktx-20250930.htm |
| 2025-08-12 | 8-K | nktx-20250812.htm |
| 2025-06-06 | 8-K | nktx-20250603.htm |
| 2025-05-14 | 8-K | nktx-20250514.htm |
| 2025-04-21 | DEF 14A | ny20043443x1_def14a.htm |